Advancements in Drug Delivery Systems in Glioblastoma Therapy
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27052298 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Purusottam Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Drug Delivery Systems, Brain Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BNW-1-036/N/5/K, Silesian University of Medicine, Silesian University of Technology.
Abstract (Originalsprache)
Glioblastoma (GB) is one of the most aggressive brain tumours, with a high mortality rate. Tumour heterogeneity, GB’s invasive nature, the blood–brain barrier (BBB) and resistance development offer significant challenges in devising an effective strategy to manage GB. Clinicians rely on tumour resection, radiotherapy and temozolomide (TMZ) chemotherapy, but their efficacy is hindered due to poor BBB penetration. EGFR (epidermal growth factor receptor), NF-κB, angiogenic pathways, RAS/RAF/MAPK, PI3K/Akt/mTOR, etc., play an important role in GB progression. Development in nanotechnology, pharmaceutical science and genetic engineering enables the design of drug candidates with superior efficacy and safety profiles. This review delves into recent advancements in nanoparticles, hydrogels, extracellular vesicles, microneedles and other drug delivery platforms used in GB treatment. These novel drug delivery systems achieved superior BBB penetration, tumour targeting, and controlled release and better survival outcomes in preclinical setups. This review also discusses the major translational challenges, including those of large-scale production, tumour heterogeneity, off-target effects and M2 macrophage induction. Innovative strategies focusing on drug delivery as a biological decision-making process, integrating tumour stress responses into drug carrier and system-level design principles, are discussed, outlining future prospects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland.
- Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun 248002, India.
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0T6, Canada.
- Paul Albrechtsen Research Institute, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
- Children Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
ORCID-Profile: Purusottam Mishra, Aleksandra Markowska, Saeid Ghavami, Jarosław Markowski, Marek J Łos
Förderung
- BNW-1-036/N/5/K
- Silesian University of Medicine
- Silesian University of Technology
Zitieren
APA
Mishra, P., Gupta, P., Markowska, A., Ghavami, S., Markowski, J., & Łos, M. J. (2026). Advancements in Drug Delivery Systems in Glioblastoma Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27052298
Vancouver
Mishra P, Gupta P, Markowska A, Ghavami S, Markowski J, Łos MJ. Advancements in Drug Delivery Systems in Glioblastoma Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27052298
BibTeX
@article{Mishra2026,
author = {Mishra, Purusottam and Gupta, Payal and Markowska, Aleksandra and Ghavami, Saeid and Markowski, Jarosław and Łos, Marek J},
title = {Advancements in Drug Delivery Systems in Glioblastoma Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27052298}
}
EUVIMED